David Hung, M.D., is the President and CEO of Nuvation Bio, a biotechnology company focused on innovative treatments. He has a strong background in the medical field, holding an M.D. from a recognized medical school and over 20 years of...

David Hung, M.D., is the President and CEO of Nuvation Bio, a biotechnology company focused on innovative treatments. He has a strong background in the medical field, holding an M.D. from a recognized medical school and over 20 years of experience in biopharmaceuticals. Under his leadership, the company has seen significant growth in both projects and value. Notably, his compensation in 2023 reached $4.32 million, largely driven by stock options, which tie his financial success to the company's performance. Intriguingly, in 2021, Dr. Hung's insider trading activity peaked at over $740 million in holdings, reflecting a high level of confidence in the company's future. He emphasizes aligning executive pay with company performance, showing a commitment to the shareholders' interests as well. Additionally, not only is he steering the company, but he is also contributing to governance by taking on the role of Chair on the Board, which gives him substantial influence over strategic decisions. David Hung is not just leading; he is also shaping the future of biopharma at Nuvation.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

N

David Hung, M.D.

Founder and CEO of Nuvation Bio

Education

M.D. from the University of California, San Francisco, School of Medicine

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

January 1, 1959 - 66 years ago

CEO of Nuvation Bio for

7 years 3 months (Apr 2018 - Present)

Previous Experience

Founder and CEO of Medivation, Inc.

Rivals

Competitors/colleagues of David Hung, M.D.

Holdings

See how much did David Hung, M.D. make over time.

As of early 2021, David Hung's holdings showed significant fluctuations, with his wealth peaking at over $740 million, reflecting both confidence and strong stock performance in Nuvation Bio. His insider trading data illustrate a vested interest in the company's success....

As of early 2021, David Hung's holdings showed significant fluctuations, with his wealth peaking at over $740 million, reflecting both confidence and strong stock performance in Nuvation Bio. His insider trading data illustrate a vested interest in the company's success. Since then, the value gradually decreased to $87.40 million in September 2023, but remained stable in the tens of millions over the following months. His ability to manage such big investments indicates his commitment and belief in the long-term strategy of the company.

No data yet.

Insider Trading

See recent insider trades of David Hung, M.D..

NVCR

4,053 shares

NVCR

Jun 5, 2024

Received

NVCR

2,427 shares

NVCR

Jun 8, 2022

Received

NVCR

814 shares

NVCR

Jun 9, 2021

Received

NUVB

$293.23M

NUVB at $5.00/share

Feb 10, 2021

Received

NVCR

2,541 shares

NVCR

Jun 10, 2020

Received

NVCR

3,359 shares

NVCR

May 22, 2019

Received

AXON

$10.00M

AXON at $18.54/share

Apr 17, 2017

Purchase

Compensation History

See how much did David Hung, M.D. make over time.

In 2023, David Hung's total compensation was valued at $4.32 million, a significant portion of which came from stock options rather than salary. He earned a base salary of $593,000 but didn't receive any bonuses that year. The largest part of his pay came from options worth $3.32 million, which aligns his income directly with the company's performance. This approach underlines a philosophy aimed at fostering a pay-for-performance culture within the organization. His previous year’s compensation totaled over $8 million, highlighting the volatility based on stock performance. David's strategy abides by good governance, demonstrating that executive compensation should reflect the business’s success and incentivize long-term growth.

Year

2023

Total Compensation

$600.33K

Salary

$593.00K

Board Justification

The compensation philosophy aligns with company performance and retention strategies, focusing on rewarding commitment and performance.

Bonus

$0.00

Board Justification

No bonus was awarded for 2023.

Other

$7.33K

Board Justification

Includes 401(k) match, life insurance premium, and commuting expenses.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was vested in 2023 as the focus is on cash compensation only.

Performance Metrics

Performance metrics are based on the achievement of pre-determined corporate goals.